United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

benefoot uk ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

benefoot uk ltd -

European Union - English - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv)

United States - English - NLM (National Library of Medicine)

bejing rimeng biological technology co ltd - salicylic acid  0.5% - salicylic acid    scalp protectant ■ shake well before use ■ apply to scalp twice a day ■ apply sufficient amount to intended area rash, irritation and/or abnormal reaction develop and last.

Australia - English - Department of Health (Therapeutic Goods Administration)

rehacare pty ltd - 33056 - bandage, cast - polyester, fibreglass and plaster used to construct a stiff dressing (cast) in order to immobilize bone fractures, diseased joints, or painful sprains.

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - sorafenib tosylate 274.0 mg eqv sorafenib - tablet, film coated - 200 mg - sorafenib tosylate 274.0 mg eqv sorafenib 200 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - sorafenib tosylate -

Israel - English - Ministry of Health

naomi shaco-ezra ltd - buprenorphine as hydrochloride; naloxone as hydrochloride dihydrate - sublingual film - buprenorphine as hydrochloride 4 mg; naloxone as hydrochloride dihydrate 1 mg - buprenorphine - suboxone sublingual film is indicated for treatment of opioid dependence in adults and adolescents over 15 years of age. suboxone sublingual film should be used as part of a complete treatment plan that includes counseling and psychosocial support.